159 related articles for article (PubMed ID: 1924448)
1. Urinary evaluation of tumor-associated antigens in urothelial bladder tumors.
Piana P; Casetta G; Cavallini A; Piantino P; Tizzani A
Prog Clin Biol Res; 1991; 370():179-84. PubMed ID: 1924448
[No Abstract] [Full Text] [Related]
2. [Urine determination of CEA, CA50 and TPA as tumor markers in bladder neoplasms].
Morote J; López-Pacios MA; Encabo G; de Torres JA
Med Clin (Barc); 1990 Jun; 95(3):119. PubMed ID: 2123505
[No Abstract] [Full Text] [Related]
3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
4. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
5. [Blood and urinary values of CEA and CA 19-9 in patients with bladder carcinoma].
Cicigoi A; Rocca Rossetti S; Piantino P; Cerchier A
Minerva Med; 1986 Nov; 77(42-43):1983-7. PubMed ID: 3464851
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological study of urinary bladder tumors. Clinical evaluation of immunohistochemistry in urine cytology].
Nagata Y; Kinoshita H; Kawamura N; Sasadaira S
Hinyokika Kiyo; 1985 Nov; 31(11):1931-7. PubMed ID: 4091136
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
[TBL] [Abstract][Full Text] [Related]
8. Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities.
Casetta G; Piana P; Cavallini A; Vottero M; Tizzani A
Br J Urol; 1993 Jul; 72(1):60-4. PubMed ID: 8149183
[TBL] [Abstract][Full Text] [Related]
9. Considerations on the use of urine markers for bladder cancer.
van Rhijn BW
Eur Urol; 2008 May; 53(5):880-1. PubMed ID: 18222604
[No Abstract] [Full Text] [Related]
10. Clinical application of NMP22 in the management of transitional cell carcinoma of the bladder.
Sawczuk IS; Bagiella E; Sawczuk AT; Yun EJ
Cancer Detect Prev; 2000; 24(4):364-8. PubMed ID: 11059567
[TBL] [Abstract][Full Text] [Related]
11. Significance of urinary tissue polypeptide specific antigen (TPS) determination in patients with urothelial carcinoma.
Yao WJ; Chang CJ; Chan SH; Chow NH; Cheng HL; Tzai TS; Lin SN
Anticancer Res; 1995; 15(6B):2819-23. PubMed ID: 8669871
[TBL] [Abstract][Full Text] [Related]
12. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
15. Carcinoembryonic antigen and urothelial carcinoma.
Hall RR; Laurence DJ; Neville AM; Wallace DM
Br J Urol; 1973 Feb; 45(1):88-92. PubMed ID: 4690154
[No Abstract] [Full Text] [Related]
16. Initial evaluation of the diagnostic performance of the new urinary bladder cancer antigen test as a tumor marker for transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megias J; Mira A; Espasa A; Chinchilla V; Soria F
J Urol; 1999 Apr; 161(4):1110-5. PubMed ID: 10081849
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder.
Allard P; Fradet Y; Têtu B; Bernard P
Clin Cancer Res; 1995 Oct; 1(10):1195-202. PubMed ID: 9815912
[TBL] [Abstract][Full Text] [Related]
18. [Serum and tissue quantification of tissue polypeptide antigen (TPA) in transitional cell carcinoma of the bladder].
Moreno Sierra J; Maestro de las Casas ML; Ortega Heredia MD; Blanco Jimenez E; Hermida Gutiérrez J; Resel Estévez L
Arch Esp Urol; 1994 Dec; 47(10):979-84. PubMed ID: 7864679
[TBL] [Abstract][Full Text] [Related]
19. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
20. The tumor markers CEA, TPA and CA 19-9 in gastric cancer.
Putzki H; Reichert B; Jablonski M; Heymann H
Dtsch Z Verdau Stoffwechselkr; 1988; 48(3-4):145-8. PubMed ID: 3234297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
